SCHEMBL5883806

SCHEMBL5883806

COc1ccc2c(c1)OC(=C1SCCCS1)c1c-2ccc2c1C(C)=CC(C)(C)N2

nearest known ligand 0.69

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 15/20 0.69
▸ NR3C1 P04150 9/20 0.69
▸ AR P10275 4/20 0.69
▸ NR3C2 P08235 2/20 0.69
▸ ESR1 P03372 2/20 0.69
▸ ESR2 Q92731 2/20 0.69
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5883207 0.82 PGR (1.00) PGRNR3C1ARNR3C2ESR1
SCHEMBL5883874 0.77 PGR (0.74) PGRNR3C1ARNR3C2ESR1
SCHEMBL5883764 0.76 PGR (0.67) PGRNR3C1ARNR3C2ESR1
SCHEMBL6650780 0.70 PGR (1.00) PGRNR3C1ARNR3C2
SCHEMBL4179241 0.69 PGR (0.78) PGRNR3C1ARNR3C2ESR1
SCHEMBL4179247 0.69 PGR (0.78) PGRNR3C1ARNR3C2ESR1
SCHEMBL4176694 0.67 PGR (0.77) PGRNR3C1ARNR3C2ESR1
SCHEMBL4176698 0.67 PGR (0.77) PGRNR3C1ARNR3C2ESR1
SCHEMBL1394706 0.67 ALDH1A1 (0.97) PGRNR3C1KDM4EMEN1ALDH1A1
SCHEMBL1322296 0.67 ALDH1A1 (0.74) PGRKDM4EMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060223839-A1 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds LIGAND PHARMACEUTICALS, INCORPORATED 2006-10-05 — — US claimed
US-7084151-B2 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds LIGAND PHARMACEUTICALS INCORPORATED (US) 2006-08-01 — — US claimed
US-20040147530-A1 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2004-07-29 — — US claimed
US-20060223839-A1 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds LIGAND PHARMACEUTICALS, INCORPORATED 2006-10-05 — — US disclosed
US-7084151-B2 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds LIGAND PHARMACEUTICALS INCORPORATED (US) 2006-08-01 — — US disclosed
US-20040147530-A1 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2004-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223839-A1 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds PGR, GPER1, PGRMC1 PGR 1/4885NR3C1 7/4885AR 24/4885
US-20040147530-A1 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds PGR, GPER1, PGRMC1 PGR 1/4885NR3C1 9/4885AR 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback